NCT04094142已完成2 期
Phase II Trial of Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
NCCN guidelines for B cell lymphoma suggest that patients with relapsed/refractory aggressive NHL who are candidate for high-dose therapy should receive combination of cytotoxic chemotherapies as 2nd line treatment. However, proportion of patients who are adequately salvaged by second line chemotherapy and high-dose chemotherapy with stem cell rescue is unsatisfactory. Moreover, many fragile patients are unfit for salvage cytotoxic chemotherapy and/or high-dose chemotherapy. Hence, most of patients with relapsed/refractory aggressive B-cell NHL is ultimately candidate for less-cytotoxic drugs with targeted approach. This trial is phase II trial of acalabrutinib in combination with rituximab and lenalidomide for these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥ 18 years of age.
- •Diagnosed with aggressive B cell non-Hodgkin lymphoma
- •Diffuse large B cell lymphoma (Both GCB and non-GCB)
- •: GCB type should not be more than 40% (N=26) of whole study population (Would limit number of GCB patients by maximum of 26)
- •Primary mediastinal B cell lymphoma
- •Transformed follicular lymphoma
- •Small lymphocytic lymphoma with Richter transformation
- •Failed previous treatments and last dose administered must be more than 2-week ahead from enrollment
- •Should have received anti-CD20 based chemotherapy previously
- •Failed at least two lines of therapy if patient is candidate for autologous stem cell transplantation
- •Failed frontline therapy if patient is ineligible for autologous stem cell transplantation
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- •Woman of childbearing potential (WOCBP) who are sexually active must have 2 negative urine hCG test prior to first dose, then every week for the first month of study period, then every 4 weeks afterwards during treatment period if menses are regular or every 2 weeks if menses are irregular. Urine hCG test must be done 4 weeks after the last dose of acalabrutinib, lenalidomide and rituximab. WOCBP must use 2 methods including at least 1 highly effective method of contraception for 4 weeks prior to first dose, during treatment period and for 4 weeks after the last dose of acalabrutinib, lenalidomide and for 12 months after the last dose of rituximab. Men who are sexually active must use condoms during treatment period and 4 weeks after the last dose of any study drug.
- •Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
- •Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information.
排除标准
- •Diagnosed with mantle cell lymphoma
- •Previously treated with more than four lines of chemotherapy (Consolidative autologous stem cell transplantation is deemed as the same line therapy)
- •Previously treated with allogeneic hematopoietic stem cell transplantation within 6 months
- •GVHD requiring treatment
- •Patient who cannot take drug per oral
- •Known resistance to both BTK inhibitor and lenalidomide (Progression free survival to both BTK inhibitor and lenalidomide < 6 months)
- •Known resistant mutation to BTK inhibitor (BTKC481S and PLGCR665W)
- •Prior malignancy (or any other malignancy that requires active treatment), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 5 years or which will not limit survival to < 5 years.
- •Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study.
- •Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
- •Known history of infection with HIV or any uncontrolled active systemic infection (eg, bacterial, viral or fungal).
- •Known history of drug-specific hypersensitivity or anaphylaxis to study drug (including active product or excipient components).
- •Active bleeding, history of bleeding diathesis (eg, hemophilia or von Willebrand disease).
- •Uncontrolled AIHA (autoimmune hemolytic anemia) or ITP (idiopathic thrombocytopenic purpura).
- •Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer.
- •Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug.
- •Prothrombin time/INR or aPTT (in the absence of Lupus anticoagulant) > 2x ULN.
- •Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment to this study.
- •History of significant cerebrovascular disease or event, including stroke or intracranial hemorrhage, within 6 months before the first dose of study drug.
- •Major surgical procedure within 28 days of first dose of study drug. Note: If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of study drug.
- •Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HbsAg) positive or hepatitis B PCR positive will be excluded. Those who are positive only for anti-HBc and negative for HbsAg and hepatitis B PCR need to receive adequate antiviral prophylaxis for hepatitis B during the study period.
- •Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded.
- •Active tuberculosis (history of exposure or history of positive tuberculin test; plus presence of clinical symptoms, physical or radiographic findings). Subjects with latent tuberculosis infection who are deemed to require treatment by the investigator are not eligible.
- •Uncontrolled active infection as determined by the investigator.
- •WBC < 3,000 /μL, ANC < 1,000 /μL, Platelets < 75,000 /μL, or Hemoglobin < 9.0 g/dL. Correction with transfusion within 2 weeks is not allowed.
- •Total bilirubin > 2 x ULN, or AST, ALT > 3 x ULN
- •Cr > 1.5 x ULN or CLcr < 30 mL/min/1.73m2
- •Breastfeeding or pregnant.
- •Concurrent participation in another therapeutic clinical trial.
研究组 & 干预措施
Treatment arm
Experimental
Acalabrutinib is provided as hard gelatin capsules for oral administration. Acalabrutinib 100 mg will be administered approximately every 12 hours from day 1 to day 28 Rituximab is provided as single-use vials for intravenous administration only. Rituximab 375 mg/m2 will be administered on day 1.
Lenalidomide is provided as opaque hard capsules for oral administration. Lenalidomide 20 mg will be administered once daily from day 1 to day 21
干预措施: Acalabrutinib (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: within 4 weeks after the 6 cycles of combination therapy (each cycle is 28 days)
ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Lugano criteria
次要结局
- Progression free survival(Tumor status will be assessed at Week 8, 16, 24 (± 7 days), then every 3 months (± 14 days))
- Duration of response(Tumor status will be assessed at Week 8, 16, 24 (± 7 days), then every 3 months (± 14 days))
- Complete remission rate(Response will be assessed at Week 8, 16, 24 (± 7 days))
- Overall survival(Tumor status will be assessed at Week 8, 16, 24 (± 7 days), then every 3 months (± 14 days))
研究者
YOUNGIL KOH
Professor
Seoul National University Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaNon-Hodgkin's LymphomaDiffuse Large B-Cell LymphomaDLBCLNHLNCT04002947National Cancer Institute (NCI)132
撤回
2 期
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell LymphomaAnaplastic Large Cell Lymphoma, ALK-PositiveNCT03719898Fox Chase Cancer Center
Unknown
2 期
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Mature B-Cell Leukemia Burkitt TypeBurkitt Lymphoma (BL)Unclassifiable Lymphoma Between DCBL and BLNCT05049473PETHEMA Foundation100
Unknown
2 期
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHLLymphoma, High-GradeNCT00385125University of Magdeburg30
招募中
2 期
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT06757647Seema Bhat61